GlassScriptPhysician profile
Donald R Jones
NPI 1649217951
$1,286.20
in general payments reported to CMS, 2019-2025
22 companies · $70.86 in 2025
The $70.86 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $103 · 2021: $408 · 2022: $95.89 · 2023: $293 · 2024: $112 · 2025: $70.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.18 | 2019-2021 | |
| Exeltis, USA INC. | $165.53 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $84.02 | 2023 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Agile Therapeutics, INC. | $82.89 | 2021-2023 | Twirla |
| Myovant Sciences INC. | $65.37 | 2021-2022 | |
| Zyla Life Sciences, INC. | $64.99 | 2020 | |
| Astellas Pharma US INC | $61.68 | 2023 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $61.08 | 2019-2025 | Bulkamid |
| Evofem Biosciences, INC. | $46.07 | 2021 | |
| Allergan, INC. | $44.25 | 2019 | |
| Organon LLC | $39.99 | 2021-2024 | |
| Lilly USA, LLC | $33.96 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Sumitomo Pharma America, INC. | $28.45 | 2024 | Gemtesa |
| Roche Diagnostics Corporation | $25.20 | 2019 | |
| Ascend Therapeutics US, LLC | $24.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $23.13 | 2023 | Bulkamid |
| Merck Sharp & Dohme LLC | $22.97 | 2021 | |
| Lsi Solutions INC | $22.02 | 2024 | Fornisee |
| Shield Therapeutics INC | $16.28 | 2023 | Accrufer |
| Novo Nordisk INC | $15.96 | 2023 | Wegovy |
| Minerva Surgical, INC | $14.15 | 2023 | |
| Mayne Pharma Commercial LLC | $12.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.